G1H Stock Overview
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
G1 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.63 |
| 52 Week High | US$4.42 |
| 52 Week Low | US$1.04 |
| Beta | 1.69 |
| 1 Month Change | -3.05% |
| 3 Month Change | 4.50% |
| 1 Year Change | 65.57% |
| 3 Year Change | -80.44% |
| 5 Year Change | -79.87% |
| Change since IPO | -74.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| G1H | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.2% | -0.2% | 0.5% |
| 1Y | 65.6% | -22.8% | 1.3% |
Return vs Industry: G1H exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: G1H exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| G1H volatility | |
|---|---|
| G1H Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G1H's share price has been volatile over the past 3 months.
Volatility Over Time: G1H's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 100 | Jack Bailey | www.g1therapeutics.com |
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer.
G1 Therapeutics, Inc. Fundamentals Summary
| G1H fundamental statistics | |
|---|---|
| Market cap | €194.15m |
| Earnings (TTM) | -€44.71m |
| Revenue (TTM) | €76.92m |
2.4x
P/S Ratio-4.2x
P/E RatioIs G1H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G1H income statement (TTM) | |
|---|---|
| Revenue | US$82.51m |
| Cost of Revenue | US$7.20m |
| Gross Profit | US$75.32m |
| Other Expenses | US$123.28m |
| Earnings | -US$47.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 91.28% |
| Net Profit Margin | -58.13% |
| Debt/Equity Ratio | 145.7% |
How did G1H perform over the long term?
See historical performance and comparison